Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 7/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.36 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | CDC25A | P30304 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4556157 | 0.91 | — | — | |
| SCHEMBL7164575 | 0.88 | — | — | |
| SCHEMBL27868483 | 0.88 | THRB (0.50) | HTTTHRBTSHRCA1CA2 | |
| SCHEMBL13551004 | 0.88 | THRB (0.50) | HTTTHRBTSHRCA1CA2 | |
| SCHEMBL12760684 | 0.88 | THRB (0.50) | HTTTHRBTSHRCA1CA2 | |
| SCHEMBL10940757 | 0.88 | — | — | |
| SCHEMBL17009071 | 0.88 | THRB (0.50) | HTTTHRBTSHRCA1CA2 | |
| SCHEMBL28160682 | 0.88 | — | — | |
| Tetrapropylammonium SCHEMBL17865413 | 0.84 | SLC22A1 (0.50) | DNM1TSHRSLC22A1SLC22A2 | |
| Tetrylammonium SCHEMBL17865405 | 0.84 | DNM1 (0.44) | DNM1HTTTHRBTSHRSLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3037398-B1 | METHOD FOR MANUFACTURING CHEMICAL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2021-03-10 | — | — | EP | disclosed |
| US-9982087-B2 | Method for producing compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20160200861-A1 | METHOD FOR PRODUCING COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-07-14 | — | — | US | disclosed |
| EP-3037398-A1 | METHOD FOR MANUFACTURING CHEMICAL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2016-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200861-A1 | METHOD FOR PRODUCING COMPOUND | NUDT1, OSGEP, CNOT9 | DNM1 1005/4885HTT 2733/4885RAD52 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.